Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €2.37 EUR
Change Today -0.13 / -5.20%
Volume 604.3K
PA8 On Other Exchanges
As of 3:35 PM 04/17/15 All times are local (Market data is delayed by at least 15 minutes).

paion ag (PA8) Snapshot

Previous Close
Day High
Day Low
52 Week High
05/28/14 - €3.51
52 Week Low
10/10/14 - €1.66
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for PAION AG (PA8)

Related News

No related news articles were found.

paion ag (PA8) Related Businessweek News

No Related Businessweek News Found

paion ag (PA8) Details

Paion AG, a specialty pharma company, develops and commercializes drug candidates for diseases or interventions. Its product candidates include Remimazolam, an ultra short-acting general anaesthetic/sedative agent, which is under various clinical studies and developed to be used in general anesthesia (deep and long sedation of up to several hours) and procedural sedation (short sedation of up to about 30 minutes) in short procedures, such as colonoscopies applications; and Glial Growth Factor 2 that completed Phase I trials to stimulate the growth and differentiation of various cells, including glial cells. Paion AG was founded in 2000 and is headquartered in Aachen, Germany.

21 Employees
Last Reported Date: 03/18/15
Founded in 2000

paion ag (PA8) Top Compensated Officers

Co-Founder, Chairman of Management Board and ...
Total Annual Compensation: €370.0K
Co-Founder, Chief Medical Officer and Member ...
Total Annual Compensation: €340.0K
Chief Financial Officer and Member of Managem...
Total Annual Compensation: €50.0K
Compensation as of Fiscal Year 2014.

paion ag (PA8) Key Developments

PAION AG Announces Initiation of US Phase III Clinical Trial of Remimazolam for Procedural Sedation During Colonoscopy

PAION AG announced the initiation of a U.S. Phase III clinical trial of Remimazolam, an ultra-short-acting sedative/anesthetic, for procedural sedation in patients undergoing colonoscopy. During Phase II clinical trials, Remimazolam displayed faster onset of sedation and greater procedural success compared to midazolam. Remimazolam showed a benign safety profile and patients experienced rapid recovery from sedation including faster recovery of cognitive function as compared to midazolam. The initiation of the Phase III trial in patients undergoing colonoscopies marks the start of PAION's Phase III clinical program, which includes a second pivotal Phase III trial in patients undergoing bronchoscopies and a third smaller safety trial in high-risk patients undergoing colonoscopies. In parallel, PAION will conduct three Phase I studies. This Phase III clinical trial is a prospective, double-blind, randomized, placebo and midazolam-controlled, U.S. multicenter study in 460 patients undergoing colonoscopies for diagnostic or therapeutic reasons. Patients will be randomized to receive Remimazolam, midazolam or placebo in addition to fentanyl to achieve moderate sedation. The primary objective of this study is to investigate the short-term sedation, and hence the success of a colonoscopy compared to placebo and midazolam. The primary endpoint is the successful completion of the colonoscopy procedure with no requirement for alternative sedative. The completion of patient recruitment is expected before the end of 2015.

Paion AG Reports Consolidated Earnings Results for the Year Ended December 31, 2014; Provides Earnings Guidance for 2015

Paion AG reported consolidated earnings results for the year ended December 31, 2014. In 2014, according to International Financial Reporting Standards (IFRS), revenues amounted to EUR 3.5 million and thus were EUR 0.8 million lower compared to 2013. The financial year 2014 closed with a net loss of EUR 9.1 million, thus exceeding the net loss of EUR 2.2 million of 2013 substantially but according to plan, due to higher research & development (R&D) expenses for the sedative Remimazolam and higher general and administrative costs. Loss per diluted share was EUR 0.23 compared to EUR 0.09 in 2013. Cash flows used in operating activities was EUR 12,044,000 compared to EUR 1,746,000 a year ago. Pretax loss widened to EUR 11.5 million from EUR 3 million a year earlier. For the 2015, the company it does not expect revenues. The net loss will expand to around EUR 25 million to EUR 29 million on higher R&D expenses of EUR 25 million to EUR 30 million and higher general administrative and selling expenses of EUR 4.5 million to EUR 5 million.

Paion AG, 2014 Earnings Call, Mar 18, 2015

Paion AG, 2014 Earnings Call, Mar 18, 2015


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PA8:GR €2.37 EUR -0.13

PA8 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PA8.
View Industry Companies

Industry Analysis


Industry Average

Valuation PA8 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 33.0x
Price/Book 1.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 14.0x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PAION AG, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at